Formic Acid

Formic Acid

SCHEMBL4663852

COc1ccc(S(=O)(=O)Nc2ccc(Nc3cc(-c4ccc5c(ccn5CC(C)N(C)C)c4)ncn3)cc2)cc1F.O=CO

nearest known ligand 0.42

Full drug profile on Sugi Atlas →

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KIT P10721 1/20 0.42
LMNA P02545 1/20 0.39
CCNT1 O60563 1/20 0.36
CDK9 P50750 1/20 0.36
SCN9A Q15858 5/20 0.36
TNNI3K Q59H18 2/20 0.36
ABL1 P00519 4/20 0.36
BCR P11274 4/20 0.36
BACE1 P56817 1/20 0.36
TP53 P04637 2/20 0.35
MAPT P10636 2/20 0.35
NPC1 O15118 1/20 0.35
HTT P42858 1/20 0.35
ADRB2 P07550 1/20 0.34
ADRB1 P08588 1/20 0.34
ADRB3 P13945 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Formic Acid SCHEMBL4665725 0.94 KIT (0.41) KITLMNACCNT1CDK9SCN9A
Formic Acid SCHEMBL4666169 0.89 HTR6 (0.46) KITLMNACCNT1CDK9
Formic Acid SCHEMBL4667419 0.87 HTR6 (0.48) KITLMNACCNT1CDK9SCN9A
SCHEMBL4663854 0.86 USP2 (0.35) KITLMNACCNT1CDK9TNNI3K
Formic Acid SCHEMBL4663865 0.85 HTR6 (0.43) KITLMNACCNT1CDK9TNNI3K
Formic Acid SCHEMBL4663848 0.85 RORC (0.35) KITABL1BCRBACE1TP53
Formic Acid SCHEMBL4667448 0.84 LMNA (0.41) KITLMNACCNT1CDK9SCN9A
SCHEMBL4665730 0.80 BACE1 (0.34) KITLMNACCNT1CDK9SCN9A
SCHEMBL4666185 0.80 LMNA (0.43) KITLMNACCNT1CDK9SCN9A
Formic Acid SCHEMBL4664389 0.79 RORC (0.34) KITCCNT1CDK9ABL1BCR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080242681-A1 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors ALTANA PHARMA AG (DE) 2008-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080242681-A1 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors MAP3K19, MAP3K6, MAP3K20 KIT 675/4885LMNA 4261/4885CCNT1 217/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.